[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Reimer
G
G
Praxis für Dermatologie und Allergologie Augsburg. g.reimer@t-online.de
Brudler
O
O
Heinrich
B
B
Bangerter
M
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis* / Q000628:therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D006201:Hair Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab